TLSA Tiziana Life Sciences Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1723069 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $5.23M | $8.11M |
| Operating income | -$15.79M | -$17.98M |
| Interest expense | $1.77M | $412,000 |
| Pretax income | -$16.75M | -$17.24M |
| Income tax | -$4.88M | $449,000 |
| Net income | -$11.86M | -$17.69M |
| EPS (basic) | -0.11 | -0.17 |
| EPS (diluted) | -0.11 | -0.17 |
| Balance sheet | ||
| Cash & equivalents | $3.72M | $1.18M |
| Current assets | $7.51M | $7.34M |
| PP&E, netmay include right-of-use assets (IFRS) | $16,000 | $10,000 |
| Total assets | $11.28M | $12.18M |
| Current liabilities | $7.35M | $6.54M |
| Total liabilities | $7.35M | $6.65M |
| Shareholders' equity | $3.94M | $5.54M |
| Cash flow statement | ||
| Operating cash flow | -$1.53M | -$15.70M |
| Capital expenditure | $19,000 | — |
| Free cash flow | -$1.54M | — |
| Investing cash flow | -$71,000 | -$1.25M |
| Financing cash flow | $4.50M | $40,000 |
| Stock-based compensation | $910,000 | $1.73M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.